# Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients

> **NCT05735197** · PHASE4 · COMPLETED · sponsor: **Mansoura University** · enrollment: 100 (actual)

## Conditions studied

- Chronic Kidney Diseases
- Bone Diseases, Metabolic

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05735197
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-01
- **Primary completion:** 2023-08-10
- **Final completion:** 2023-11-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05735197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05735197, "Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05735197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*